Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice
Lei Xia,1,* Li Wen,1,2,* Xiangxi Meng,1 Nina Zhou,1 Xiaoyi Guo,1 Teli Liu,1 Xiaoxia Xu,1 Feng Wang,1 Hua Zhu,1 Zhi Yang1 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceutica...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/96da9df0855048c999bbc4b3c4fd8012 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:96da9df0855048c999bbc4b3c4fd8012 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:96da9df0855048c999bbc4b3c4fd80122021-12-02T19:29:16ZApplication Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice1178-2013https://doaj.org/article/96da9df0855048c999bbc4b3c4fd80122021-11-01T00:00:00Zhttps://www.dovepress.com/application-analysis-of-124i-ppmn-for-enhanced-retention-in-tumors-of--peer-reviewed-fulltext-article-IJNhttps://doaj.org/toc/1178-2013Lei Xia,1,* Li Wen,1,2,* Xiangxi Meng,1 Nina Zhou,1 Xiaoyi Guo,1 Teli Liu,1 Xiaoxia Xu,1 Feng Wang,1 Hua Zhu,1 Zhi Yang1 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 2Guizhou University School of Medicine, Guiyang, Guizhou, 550025, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hua Zhu; Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of ChinaTel +86 010-88196196; +86 010-88196495Email zhuhuananjing@163.com; pekyz@163.comBackground: In recent years, nuclear medicine imaging and therapy for prostate cancer have radically changed through the introduction of radiolabeled prostate-specific membrane antigen (PSMA)-binding peptides. However, these small molecular probes have some inherent limitations, including high nephrotoxicity and short circulation time, which limits their utility in biological systems.Methods and Results: In this study, organic melanin nanoparticles were used to directly label the long half-life radionuclide 124I (t1/2=100.8 h), and PSMA small molecular groups were efficiently bonded on the surface of nanoparticles to construct the PSMA-targeted long-retention nanoprobe 124I-PPMN, which has the potential to increase tumor uptake and prolong residence time. The results showed that the nanoprobe could substantially aggregate in the tumors of prostate cancer xenograft mice and was visible for more than 72 h. Positron Emission Computed Tomography (PET) imaging showed that the nanoprobe could be used for precise imaging of prostate cancer with high expression of PSMA. In addition, organic melanin nanoparticles labeled with an elemental radionuclide achieved a stable, metal-free structure. Cell experiments and mouse toxicity experiments indicated that the nanoprobe has high safety.Conclusion: The new nanoprobe constructed in this study has high specificity and biocompatibility. In the future, combined with the multifunctional potential of melanin nanoparticles, this nanoprobe is expected to be used in the integrated theranostics of prostate cancer.Keywords: prostate cancer, 124I, PET, PSMA, melanin nanoparticlesXia LWen LMeng XZhou NGuo XLiu TXu XWang FZhu HYang ZDove Medical Pressarticleprostate cancer124ipetpsmamelanin nanoparticlesMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 7685-7695 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
prostate cancer 124i pet psma melanin nanoparticles Medicine (General) R5-920 |
| spellingShingle |
prostate cancer 124i pet psma melanin nanoparticles Medicine (General) R5-920 Xia L Wen L Meng X Zhou N Guo X Liu T Xu X Wang F Zhu H Yang Z Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice |
| description |
Lei Xia,1,* Li Wen,1,2,* Xiangxi Meng,1 Nina Zhou,1 Xiaoyi Guo,1 Teli Liu,1 Xiaoxia Xu,1 Feng Wang,1 Hua Zhu,1 Zhi Yang1 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 2Guizhou University School of Medicine, Guiyang, Guizhou, 550025, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hua Zhu; Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of ChinaTel +86 010-88196196; +86 010-88196495Email zhuhuananjing@163.com; pekyz@163.comBackground: In recent years, nuclear medicine imaging and therapy for prostate cancer have radically changed through the introduction of radiolabeled prostate-specific membrane antigen (PSMA)-binding peptides. However, these small molecular probes have some inherent limitations, including high nephrotoxicity and short circulation time, which limits their utility in biological systems.Methods and Results: In this study, organic melanin nanoparticles were used to directly label the long half-life radionuclide 124I (t1/2=100.8 h), and PSMA small molecular groups were efficiently bonded on the surface of nanoparticles to construct the PSMA-targeted long-retention nanoprobe 124I-PPMN, which has the potential to increase tumor uptake and prolong residence time. The results showed that the nanoprobe could substantially aggregate in the tumors of prostate cancer xenograft mice and was visible for more than 72 h. Positron Emission Computed Tomography (PET) imaging showed that the nanoprobe could be used for precise imaging of prostate cancer with high expression of PSMA. In addition, organic melanin nanoparticles labeled with an elemental radionuclide achieved a stable, metal-free structure. Cell experiments and mouse toxicity experiments indicated that the nanoprobe has high safety.Conclusion: The new nanoprobe constructed in this study has high specificity and biocompatibility. In the future, combined with the multifunctional potential of melanin nanoparticles, this nanoprobe is expected to be used in the integrated theranostics of prostate cancer.Keywords: prostate cancer, 124I, PET, PSMA, melanin nanoparticles |
| format |
article |
| author |
Xia L Wen L Meng X Zhou N Guo X Liu T Xu X Wang F Zhu H Yang Z |
| author_facet |
Xia L Wen L Meng X Zhou N Guo X Liu T Xu X Wang F Zhu H Yang Z |
| author_sort |
Xia L |
| title |
Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice |
| title_short |
Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice |
| title_full |
Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice |
| title_fullStr |
Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice |
| title_full_unstemmed |
Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice |
| title_sort |
application analysis of 124i-ppmn for enhanced retention in tumors of prostate cancer xenograft mice |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/96da9df0855048c999bbc4b3c4fd8012 |
| work_keys_str_mv |
AT xial applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice AT wenl applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice AT mengx applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice AT zhoun applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice AT guox applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice AT liut applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice AT xux applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice AT wangf applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice AT zhuh applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice AT yangz applicationanalysisof124ippmnforenhancedretentionintumorsofprostatecancerxenograftmice |
| _version_ |
1718376452797235200 |